December 19, 2019 – First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response
[See Milestones above for detail]

Fondation Merieux [to 21 Dec 2019]
News, Events
20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)

Gavi [to 21 Dec 2019]
No new digest content identified.

GHIT Fund [to 21 Dec 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 21 Dec 2019]
News & Stories
Technical Evaluation Reference Group: Market Shaping Strategy Mid-Term Review
20 December 2019
Thematic Review of Market Shaping Strategy (Mid-Term) download in English

Highest-Ever Funding Allocations Announced to Fight AIDS, TB and Malaria
18 December 2019
[See Milestones above for detail]

Feature Story
2019: A Record Year for Global Health
17 December 2019

Hilleman Laboratories [to 21 Dec 2019]
No new digest content identified.

Human Vaccines Project [to 21 Dec 2019]
Press Releases
No new digest content identified.

IAVI [to 21 Dec 2019]
December 18, 2019
EDCTP-Funded Clinical Trial of New TB Vaccine Initiates Vaccinations
Partners collaborate in trial to evaluate whether vaccine candidate can prevent recurrence of TB disease
18 DECEMBER 2019 — Statens Serum Institut (SSI) in Copenhagen, Denmark, is the coordinator of a consortium that has been granted EUR 13.8 million from the European & Developing Countries Clinical Trial Partnership (EDCTP) supported by the European Union. The grant finances a clinical trial in South Africa and Tanzania of a new and promising tuberculosis (TB) vaccine candidate H56:IC31* developed by SSI. SSI and Aeras Global TB Vaccine Foundation NPC (a South African affiliate of IAVI) are co-sponsors of the trial.
The consortium consists of partners from South Africa, Tanzania, Italy, and Denmark: the South African Tuberculosis Vaccine Initiative (SATVI; Cape Town, South Africa), University of Cape Town Lung Institute (Cape Town, South Africa), TASK Applied Science (Cape Town, South Africa), the Aurum Institute (Johannesburg, South Africa), the National Institute for Medical Research (NIMR; Mbeya, Tanzania), Ospedale San Raffaele (Milan, Italy), the Aeras Global TB Vaccine Foundation NPC (Cape Town, South Africa), and SSI (a governmental research institution under the Danish Ministry of Health)…

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.

No new digest content identified.

IFRC [to 21 Dec 2019]
Selected Press Releases, Announcements
No new digest content identified.

IVAC [to 21 Dec 2019]
No new digest content identified.

IVI [to 21 Dec 2019]
Selected IVI News & Announcements
IVI appoints three new members to its Board of Trustees
December 18, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI), a Seoul, Korea-based international organization dedicated to accelerating vaccines for global health, announced today that Professor Gordon Dougan, Dr. Melanie Saville, and Dr. Jean-Marie Okwo-Bele will join its Board of Trustees (BOT) early next year. The three new members were elected at a face-to-face board meeting last month, and their terms will commence at the end of the next BOT meeting, scheduled for February 27, 2020.
“I’m very pleased to announce that three exemplary leaders across vaccinology, vaccine development and Global Health have joined the IVI Board of Trustees,” said Dr. Jerome Kim, Director General of IVI. “As we continue to diversify our vaccine portfolio and expand into different research areas, we and our global network of partners will greatly benefit from the expertise and guidance of Professor Dougan, Dr. Saville, and Dr. Okwo-Bele.”
:: Professor Gordon Dougan, GSK Professor, Department of Medicine at Cambridge University
:: Dr. Melanie Saville, Director of Vaccine Development, Coalition for Epidemic Preparedness Innovations (CEPI)
:: Dr. Jean-Marie Okwo-Bele, Independent Public Health Consultant

JEE Alliance [to 21 Dec 2019]
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 21 Dec 2019]
Latest [Selected Announcements]
Democratic Republic of Congo
Extra humanitarian assistance urgently needed in southern North Kivu crisis
Press Release 16 Dec 2019
:: A little-known humanitarian crisis is affecting the territories of Masisi, Rutshuru and Walikale in the southern part of DRC’s North Kivu province.
:: More than 685,000 displaced people live in camps or are hosted by local families, with worrying levels of malnutrition and sexual violence.
:: With almost no aid organisations on the ground, MSF urges humanitarian organisations and donors to immediately return to this neglected area.

National Vaccine Program Office – U.S. HHS [to 21 Dec 2019]
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

NIH [to 21 Dec 2019]
Selected News Releases
Infectious Diseases Clinical Research Consortium awards announced
New NIH grants build on established clinical trials program.
Thursday, December 19, 2019
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group. NIAID intends to provide approximately $29 million per year for seven years for the VTEU program and its companion leadership group.
The consortium leadership group will be headed by co-principal investigators David S. Stephens, M.D., of Emory University, and Kathleen M. Neuzil, M.D., M.P.H., of the University of Maryland School of Medicine. The group will include VTEU investigators as well as scientific experts in infectious diseases who will prioritize candidate vaccines, diagnostics, therapeutics and other interventions to test in clinical trials. To respond to public health emergencies, the leadership group will have the capacity to rapidly organize and initiate clinical trials at the VTEU sites. It also will coordinate activities with VTEU sites implementing specific clinical trials and with scientific staff in the NIAID Division of Microbiology and Infectious Diseases (DMID).
The nine VTEUs are located at institutions across the United States. They will conduct Phase 1 through 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners. Depending on the disease or condition, the VTEUs may establish study sites and enroll participants at locations outside the United States. Additionally, sites will have the capacity to conduct human challenge trials—where healthy volunteers are exposed to infection under tightly controlled conditions—of influenza, malaria and other diseases….

NIH-developed Zika vaccine improves fetal outcomes in animal model
December 19, 2019 — Zika virus is primarily transmitted to humans by Aedes mosquitoes.

Children with HIV score below HIV-negative peers in cognitive, motor function tests
December 18, 2019 — Disparity worsens over time despite early HIV treatment, NIH study finds.

PATH [to 21 Dec 2019]
Selected Announcements
New pneumococcal vaccine from Serum Institute of India achieves WHO prequalification
December 19, 2019 by Lauren Newhouse
This milestone marks a key step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low- and middle-income countries
Pune, India and Seattle, United States, December 19, 2019—PNEUMOSIL®, a vaccine against a leading cause of deadly childhood pneumonia—the pneumococcus bacterium—has achieved prequalification by the World Health Organization (WHO). Developed though a collaboration spanning over a decade between Serum Institute of India, Pvt., Ltd. (SIIPL) and PATH and with funding from the Bill & Melinda Gates Foundation, the vaccine is expected to provide protection for children on par with other pneumococcal conjugate vaccines at a price that is more affordable for low- and middle-income countries…

Sabin Vaccine Institute [to 21 Dec 2019]
Statements and Press Releases
No new digest content identified.

UNAIDS [to 21 Dec 2019]
Selected Press Releases/Reports/Statements
18 December 2019
Health kiosks expanding HIV services in Zimbabwe

18 December 2019
Communities are making the difference in the HIV response

17 December 2019
Young people and men less likely to know their HIV status

UNICEF [to 21 Dec 2019]
Selected Statements, Press Releases, Reports
Press release
Waves of protests around the world are reminder that voices of children and adolescents must be heard and their rights protected
Statement by UNICEF Executive Director Henrietta Fore

Vaccination Acceptance Research Network (VARN) [to 21 Dec 2019]
No new digest content identified.

Vaccine Confidence Project [to 21 Dec 2019]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 21 Dec 2019]
December 2019

Wellcome Trust [to 21 Dec 2019]
Opinion | 18 December 2019
This is the decade we made one of the world’s deadliest diseases preventable and curable
by Jeremy Farrar
The commitment to research during the last two Ebola outbreaks has changed the course of this disease. Jeremy Farrar reflects on what made this possible.

Opinion | 18 December 2019
How ‘connectors’ bridge the gap between research and the public
by Carla Ross

News | 17 December 2019
Stellar science and research funded by another year of strong investment returns
Strong investment returns in 2019 mean Wellcome has been able to spend over £1.1 billion on improving health for everyone.

The Wistar Institute [to 21 Dec 2019]
Press Release Dec. 19, 2019
The Wistar Institute Received Nearly $2.5M in Philanthropic Support
PHILADELPHIA — (Dec. 19, 2019) — In the past six months, scientists at The Wistar Institute received funding from private foundations totaling $2,418,000 that will fuel new discoveries in cancer, immunology and infectious diseases.

World Organisation for Animal Health (OIE) [to 21 Dec 2019]
No new digest content identified.


ARM [Alliance for Regenerative Medicine] [to 21 Dec 2019]
No new digest content identified.

BIO [to 21 Dec 2019]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 21 Dec 2019]
No new digest content identified.

IFPMA [to 21 Dec 2019]
Selected Press Releases, Statements, Publications
No new digest content identified.

PhRMA [to 21 Dec 2019]
Selected Press Releases, Statements
No new digest content identified.